Testing Hydeal Cyst with standard treatment for bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a bladder instillation called Hydeal Cyst, given alongside standard BCG or MMC therapy, to see if it helps reduce side effects or improve outcomes for people with non-muscle invasive bladder cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with non-muscle invasive bladder cancer (cancer that has not spread into the deeper bladder muscle).
- You are about to start induction therapy with BCG or MMC (standard bladder treatments given after tumor removal).
- You had a bladder tumor resection surgery (TURBT) in the last 12 weeks.
- You have mild to moderate urinary symptoms (IPSS score of 19 or less).
- You do not have a current urinary tract infection, cancer in the upper urinary tract, or severe bladder narrowing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether bicalutamide can improve outcomes for people with non-muscle-invasive bladder cancer who are starting BCG through the bladder. It may help prevent cancer from coming back or progressing after BCG.
This Phase 2 trial tests TARA-002 given directly into the bladder to treat high-grade non–muscle-invasive bladder cancer with active disease. It may help patients who have not previously responded to, or have not received, BCG treatment in the recent past.
This trial tests a new drug, 2141-V11, for people with bladder cancer that has not gone away after standard treatments like BCG therapy. It may help those with non-muscle invasive bladder cancer or, in one group, muscle-invasive bladder cancer, who cannot have or choose not to have bladder removal surgery.
This trial tests a new treatment called NDV01 KIT for people with high-grade non-muscle invasive bladder cancer that hasn't gotten better after BCG therapy. It's for those who cannot or choose not to have their bladder removed.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.